Last reviewed · How we verify
recombinant human hyaluronidase PH20 — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
recombinant human hyaluronidase PH20 (recombinant human hyaluronidase PH20) — Halozyme Therapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| recombinant human hyaluronidase PH20 TARGET | recombinant human hyaluronidase PH20 | Halozyme Therapeutics | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- recombinant human hyaluronidase PH20 CI watch — RSS
- recombinant human hyaluronidase PH20 CI watch — Atom
- recombinant human hyaluronidase PH20 CI watch — JSON
- recombinant human hyaluronidase PH20 alone — RSS
Cite this brief
Drug Landscape (2026). recombinant human hyaluronidase PH20 — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-human-hyaluronidase-ph20. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab